The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward
Bayer provided an update on its five-point plan to address future Roundup litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to the closure of this litigation. The first scenario is based on obtaining a favourable decision by the US Supreme Court on a cross-cutting issue like federal preemption which would effectively and largely end the US Roundup litigation. The second scenario assumes that the Supreme Court either declines to hear the Hardeman case or issues a ruling in favour of the plaintiff – in that case, the company would activate its claims administration programme.
The company sees good chances for the first scenario and believes there are strong arguments for the US Supreme Court to accept the case and ultimately render a supporting verdict. However, Bayer is also prepared for the second scenario to manage anticipated claims, through settlement and litigation, to ultimately bring an end to this litigation. For this second scenario, the company posts an additional provision of a gross amount of $4.5 billion (3.8 billion euros), i.e. before tax and discounting in the second quarter of 2021, reflecting the company’s potential long-term exposure.
The company will file its petition seeking Supreme Court review of the Hardeman case in August. If the Supreme Court grants review, the Court will likely render a final decision in 2022. Given this impending schedule, Bayer will be very selective in its settlement approach in the coming months and will not entertain any further settlement discussions when and if the Supreme Court grants review.
In case of a negative Supreme Court outcome, Bayer would set up a professionally run claims’ administration programme that will come with pre-determined compensation values whose amounts will be similar to the values for current inventory settlements, but net of plaintiffs’ lawyers commission. The programme would address eligible individuals directly, who used Roundup previously and develop NHL over the next 15 years. This would cover any alleged NHL latency period, although regulators consistently conclude that the large body of science does not support a causal relationship between NHL and glyphosate and despite substantially different scientific opinions on the latency.
As part of the five-point plan, the company will also take additional steps to help close the door on this litigation and ensure that any claims brought by individuals who use Roundup in the future are few and unlikely to succeed. These measures include that the company and its partners will replace its glyphosate-based products in the US residential Lawn & Garden market with new formulations that rely on alternative active ingredients beginning in 2023, subject to a timely review by the US Environmental Protection Agency (EPA) and state counterparts.
Moreover, the company will engage in discussions with EPA about Roundup labels to provide more information to users about the science as an additional element towards ensuring even more informed purchasing and application decisions. It will also set up a new website with scientific studies relevant to Roundup’s safety that will provide even more transparency to purchasers about the products they use. The website is expected to be launched by the end of 2021.
